News
NPCE
9.95
+2.58%
0.25
Weekly Report: what happened at NPCE last week (1118-1122)?
Weekly Report · 6h ago
Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements
TipRanks · 3d ago
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
NASDAQ · 11/18 14:55
Weekly Report: what happened at NPCE last week (1111-1115)?
Weekly Report · 11/18 11:58
NeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy Rating
TipRanks · 11/14 07:39
NeuroPace Price Target Cut to $13.00/Share From $15.00 by Wells Fargo
Dow Jones · 11/13 17:29
NeuroPace Is Maintained at Overweight by Wells Fargo
Dow Jones · 11/13 17:29
Wells Fargo Maintains Overweight on NeuroPace, Lowers Price Target to $13
Benzinga · 11/13 17:19
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zai Lab (ZLAB), NeuroPace (NPCE) and CervoMed (CRVO)
TipRanks · 11/13 13:30
NeuroPace price target lowered to $13 from $15 at Wells Fargo
TipRanks · 11/13 11:16
NEUROPACE INC <NPCE.O>: WELLS FARGO CUTS TARGET PRICE TO $13 FROM $15
Reuters · 11/13 10:49
NeuroPace’s Strong Financial Performance and Strategic Advancements Justify Buy Rating
TipRanks · 11/13 10:42
*NeuroPace Raises 2024 View To Rev $78M-$80M >NPCE
Dow Jones · 11/12 22:14
NeuroPace raises FY24 revenue view to $78M-$80M from $76M-$78M
TipRanks · 11/12 21:56
NeuroPace Raises FY2024 Sales Guidance from $76.00M-78.00M to $78.00M-80.00M
Benzinga · 11/12 21:24
Press Release: NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Dow Jones · 11/12 21:05
NeuroPace Inc.: Q3 Earnings Snapshot
Barchart · 11/12 15:53
Weekly Report: what happened at NPCE last week (1104-1108)?
Weekly Report · 11/11 12:17
NeuroPace submits safety, effectiveness data from RNS System study to FDA
TipRanks · 11/04 21:55
Weekly Report: what happened at NPCE last week (1028-1101)?
Weekly Report · 11/04 12:12
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.